 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| 123» |
- || Tollovir (NLC-V-01) / Todos Medical
@G_Commish @todosmedical Please look into @tollovid #Tollovid #Tollovir #LongCovid #LongCovidAwarenessDay #LongCovidAwarenessMonth (Twitter) - Mar 10, 2023
- |||| Selzentry (maraviroc) / ViiV Healthcare, Tollovir (NLC-V-01) / Todos Medical, Vyrologix (leronlimab) / CytoDyn, Vyera Pharma, amfAR
Preprint: Yes #Maraviroc is a #CCR5 inhibitor. Love to hear the rationale on why its better suited in #LongCovid over #leronlimab & #tollovir which we hear are also a CCR5 antagonists. Curious if read preprint on #galectin3 & perhaps its potential in #PASC #COVID19 https://t.co/GHlWtO1OyO (Twitter) - Jan 12, 2023
- ||| Tollovir (NLC-V-01) / Todos Medical
Time for an EUA for Tollovir and Antiviral Tollovid, by Todos Medical !!!! (Twitter) - Dec 25, 2022
- ||||| Tollovir (NLC-V-01) / Todos Medical, Paxlovid (nirmatrelvir and ritonavir) / Pfizer
P2 data: @AshishKJha46 Read about Todos Medical with Tollovir (out of Phase 2 ) and also Tollovid, over the counter. 3CL Protease Inhibitor better than Paxlovid. (Twitter) - Dec 22, 2022
- || Tollovir (NLC-V-01) / Todos Medical
You should have a look on @todosmedical #Tollovid #tollovir $TOMDF. A serious Company with a promising product (Twitter) - Dec 21, 2022
- |||| Tollovir (NLC-V-01) / Todos Medical
Clinical: None yet. We are planning to conduct some soon as we raise funding for 3CL Pharma. We have completed an RCT in hospitalized patients for NLC-V (Tollovir). We presented at World Antiviral Congress 2 weeks ago alongside Shianogi and several others. NLC-V is 3CLpro/CCR5 blocker (Twitter) - Dec 11, 2022
- |||| Tollovir (NLC-V-01) / Todos Medical
P2 data: Get some Tollovid and start talking about Todos Medical with “Tollovir”, out of phase 2. It could help a lot of people. (Twitter) - Dec 10, 2022
- |||||| Tollovir (NLC-V-01) / Todos Medical
Clinical, P2 data: @DrIanWeissman Doc, check out the results on Tollovir by Todos Medical. Phase 2 results from last February. The work of Dr Dorit Arad. 3CL Protease Inhibitor science. They also have Tollovid, much weaker, OTC. Tollovir has the potential to go antibiotic and works in Pediatrics (Twitter) - Dec 10, 2022
- ||| Tollovir (NLC-V-01) / Todos Medical
Hey man! Checkout @3clPharma @todosmedical and @provistadx. We are focused on Root Cause #viralpersistence #Tollovir #TolloTest #Tollovid (not approved to diagnose, treat, prevent or cure) (Twitter) - Dec 2, 2022
- | Tollovir (NLC-V-01) / Todos Medical
@G_Commish maybe you should work with Munro & Associates to developed @todosmedical and raise the fund to launch #tollovir to the world ? (Twitter) - Nov 16, 2022
- ||| Tollovir (NLC-V-01) / Todos Medical, Paxlovid (nirmatrelvir and ritonavir) / Pfizer
Clinical: That means ideally a 37% lower risk with vaccination and 5 days of paxlovid. 10 days paxlovid and tollovid/tollovir for 90 days for viral clearance should be studied in a trial. (Twitter) - Nov 6, 2022
- || Tollovir (NLC-V-01) / Todos Medical
I am among them. But that’s ok. The need has only grown stronger. If the idea was that the weak would die out, turns out that is not what happens. They find a way to survive and that becomes chronic illness. Government will have to address it. #Tollovir https://t.co/lKioNmT9Qb (Twitter) - Oct 27, 2022
- || Tollovir (NLC-V-01) / Todos Medical, Paxlovid (nirmatrelvir and ritonavir) / Pfizer
@CathieDWood Please note root cause of US inflation intractibility is disabled workforce from #LongCOVID. @todosmedical $TOMDF sub #3CLPharma has supplement #Tollovid, drug #Tollovir & #TolloTest all targeting same mechanism as $PFE #Paxlovid @jonnajarian https://t.co/p7ZvhpUPsQ (Twitter) - Sep 19, 2022
- || Tollovir (NLC-V-01) / Todos Medical
Is @EricTopol even aware of #Tollovir ? Or is he just ignoring it? (Twitter) - Sep 1, 2022
- ||| Tollovir (NLC-V-01) / Todos Medical
How about Tollovir and Tollovid by Todos Medical. Both products are better than anything Phizer has to offer. (Twitter) - Aug 30, 2022
- ||| Tollovir (NLC-V-01) / Todos Medical
Clinical: Also that Tollovir have interesting results, suggests me, that they know what they are doing. But their safety data needs to get better. (Twitter) - Aug 5, 2022
- ||| Tollovir (NLC-V-01) / Todos Medical
Tollovir is also 3CLpro inhibitor, but a bit stronger, as I understand. I have seen a lot reliable longhaulers on Twitter who are seeing really good results with Tollovid. And I believe that viral persistence is the reason of longcovid. So, I believe in the mechanism. (Twitter) - Aug 5, 2022
- ||| Tollovir (NLC-V-01) / Todos Medical
Clinical, P2 data: But have you seen any published data on Tollovid acting as 3CLpro inhibitor. I haven't. You have just to trust the manufacturer. Tollovir is a different thing, as it is used in a phase 2 trial in Israel (hospitalised patients) (Twitter) - Aug 5, 2022
- ||| Tollovir (NLC-V-01) / Todos Medical
I just saw a post about Tollovir. Like just now. I guess I’m not paying attention. I read everything I could find in 2020 about Covid 19 then this year I just kinda slacked (Twitter) - Aug 1, 2022
- ||| Tollovir (NLC-V-01) / Todos Medical
Clinical: Tollovir is already way ahead as far as protease inhibitors for inpatient hospitalized patients in a capsule form. I expect an Israeli EUA this year. (Twitter) - Jul 24, 2022
- || Tollovir (NLC-V-01) / Todos Medical
Yikes. We need better than that. Perhaps Tollovir will live up to its promise (or something else around the corner). (Twitter) - Jul 17, 2022
- ||| A combination of bebtelovimab, evusheld,Xocova-Tollovir-ensovibep should prevent infection. Microdosing drugs in food supply with antibodies may be enough to end the pandemic. (Twitter) - Jul 15, 2022
- ||| Tollovir (NLC-V-01) / Todos Medical
Clinical: Also, any update on the Compassion Use Case of Tollovir in Israel? Is that still on the table for patients and is it being used at all? (Twitter) - Jul 7, 2022
- || Tollovir (NLC-V-01) / Todos Medical
The mutation is not in the receptor binding domain, the calatylic active site, which is what Tollovid and Tollovir target. (Twitter) - Jun 29, 2022
- || Tollovir (NLC-V-01) / Todos Medical
@thanks for the quick response. Wasn’t sure about this newly identified mutations of Mpro was an issue that @EricTopol shared. So Tollovid and Tollovir still not impacted by mutations. Really excited about ur presentation this week. @jimcramer @jonnajarian (Twitter) - Jun 29, 2022
- | Tollovir (NLC-V-01) / Todos Medical
Good report. It seems to confuse the use of tollovid v. tollovir. Typical for TV editing. (Twitter) - Jun 24, 2022
- | Tollovir (NLC-V-01) / Todos Medical
Time to look at @todosmedical @tollovid #Tollovir @G_Commish ! (Twitter) - Jun 17, 2022
- ||| Tollovir (NLC-V-01) / Todos Medical
P2 data: can't tell if that's sarcasm or not. unecessary if so since I was just answering your question, not bragging on the robustness of their proofs. Are you interested in reviewing their super small phase 2 study on nearly identical Tollovir? NRN (Twitter) - Jun 2, 2022
- || Tollovir (NLC-V-01) / Todos Medical
They can try Tollovid and Tollovir (Twitter) - Jun 1, 2022
- | Tollovir (NLC-V-01) / Todos Medical
Preclinical, Journal: Development of Tea Seed Oil Nanostructured Lipid Carriers and In Vitro Studies on Their Applications in Inducing Human Hair Growth. (Pubmed Central) - May 30, 2022
In this study, tea seed oil loaded nanostructured lipid carriers (NLC) using Tween 80 (NLC-T), Varisoft 442 (NLC-V), and a combination of both surfactants (NLC-C) was developed...In conclusion, the developed NLC-C of tea seed oil is an effective alternative in stimulating hair growth. Hair serum containing NLC-C obviously reduces sticky, oily, and greasy feeling after use.
- || Tollovir (NLC-V-01) / Todos Medical
@WesElyMD are you familiar with Dr. Dorit Arad from Israel. She has been leading the charge for Tollovid and Tollovir with her expertise in 3cl protease. Very exciting this has had positive outcomes. (Twitter) - May 14, 2022
- ||| Tollovir (NLC-V-01) / Todos Medical
Got it. Thank you for the explanation! Very helpful. I’m worrying about some ingredients in Tollovir/Tollovid, which might connect with Liver cancer. The company does make it very clear so far… (Twitter) - May 14, 2022
- || Tollovir (NLC-V-01) / Todos Medical
There are anti-warburg agents such as Aprepitant and Tollovir/Tollovid which require study to see their full potential in LC - so far, they seem to be far more efficacious than fasting (Twitter) - May 14, 2022
- || Tollovir (NLC-V-01) / Todos Medical
Do they know about Tollovir. Seems they don’t. Don’t hear anything mentioned (Twitter) - May 8, 2022
- || Tollovir (NLC-V-01) / Todos Medical, Paxlovid (nirmatrelvir and ritonavir) / Pfizer
Where Paxlovid works Tollovir will work better. The mechanism of 3CLpro is the right mechanism. This is going to take a global effort. Governments have been playing small ball. They are in for rude awakening (Twitter) - May 8, 2022
- || Tollovir (NLC-V-01) / Todos Medical, Paxlovid (nirmatrelvir and ritonavir) / Pfizer
Gerald is your product Paxlovid or Tollovir? Sometimes I wonder! (Twitter) - May 8, 2022
- ||| Tollovir (NLC-V-01) / Todos Medical
May I ask when you intend to start studying Tollovir on #longcovid ? (Twitter) - May 5, 2022
- |||| Tollovir (NLC-V-01) / Todos Medical
Clinical: Tollovir drug candidate has been focused in the hospital. We have always said we intend to expand that into peds and other settings. Yes Long COVID also makes sense. Tollovid just a supplement for now (Twitter) - May 1, 2022
- || Tollovir (NLC-V-01) / Todos Medical
Surprised Yozma hasn't helped Todos penetrate the South Korean market with either Tollovid or Tollovir......... (Twitter) - Apr 29, 2022
- ||| Tollovir (NLC-V-01) / Todos Medical
Clinical: Yes, that’s a target market for Tollovid, not Tollovir (prescription). We are upping our game w/better answer to the tox/safety questions & putting together better marketing materials as all our money to date has been invested in product development and research. We have early /1 (Twitter) - Apr 29, 2022
- || Tollovir (NLC-V-01) / Todos Medical
TY for sendig this. This is a decent start. personally I'd like to see someing looking more at likey what you are doing in your office: adding Tollovir in apopulation where you are already using RAT, if you can find a situation where RAT 2x/week is not working well. (Twitter) - Apr 29, 2022
- ||| Tollovir (NLC-V-01) / Todos Medical
Clinical: We did a hospital trial already with Tollovir. It’s definitely what is going on. https://t.co/lKioNmT9Qb (Twitter) - Apr 29, 2022
- |||| Tollovir (NLC-V-01) / Todos Medical
Clinical, P2 data: Yes, Tollovid is a less concentrated version of Tollovir. Thats a manufacturers claim, not a medical claim. Tollovir underwent a hospitalized phase 2 trail treating covid patients. They can say Tollovir can treat covid. Several hospitals in Israel treating patients with it. (Twitter) - Apr 28, 2022
- ||| Tollovir (NLC-V-01) / Todos Medical
Clinical, P2 data, HEOR: Do you have the tweets whereby he continued making health claims in regards to Tollovid? Tollovir underwent a Phase 2 clinical trial, not as concerned as its going through regulatory process. I think that bizarre tweet was sarcasm. (Twitter) - Apr 28, 2022
- || Tollovir (NLC-V-01) / Todos Medical
Much of this regarding Tollovid/Tollovir has been circulating since 2021. They received a cease and desist letter in January 2021 which someone shared on here. The content is all out there. If FDA or FTC had issue, we would have already seen action. This isn't a new issue. (Twitter) - Apr 28, 2022
- ||| Tollovir (NLC-V-01) / Todos Medical
Review: Already seeing it here with Tollovid/Tollovir. But of course, Todos likely expects that scrutiny. Yin and Yang. More scrutiny means exposure, MD review, and testimonials from users. Appreciate you @RandallBurns5 looking into this and actually testing (Twitter) - Apr 28, 2022
- || Tollovir (NLC-V-01) / Todos Medical
Tollovir is an investigational product, so it’s not a claim. We do make both products so no one besides us know wtf they’re talking about. Trying to dumb things down is tough. Sorry if the example isn’t good enough for you (Twitter) - Apr 28, 2022
- ||| Tollovir (NLC-V-01) / Todos Medical
Clinical: Gerald: "Really Tollovir is a more concentrated version of this Tollovid, and so they're not exactly the same, Tollovid is not approved to diagnose treat prevent or cure any disease, but Tollovir is, and what we're seeing with people using it, they're getting, uh, ... (Twitter) - Apr 28, 2022
- ||| Tollovir (NLC-V-01) / Todos Medical
Gerald, I'm not convinced you are making it entirely clear Are you permitted to make the claim that Tollovid is a less concentrated version of Tollovir, and that Tollovir is approved to diagnose treat, prevent, or cure any disease? See quick rough transcript I drafted below (Twitter) - Apr 28, 2022
- || Tollovir (NLC-V-01) / Todos Medical
Exactly this letter is nonsense. In all liklihood, FTC probably mixed up Tollovir/Tollovid. I am seeing some MD Tollovid naysayers doing the same exact thing. They can't distinguish between products which kinda shows they aren't really digging into the story, just attacking. (Twitter) - Apr 27, 2022